Search results

753 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Hypertension in adults: diagnosis and management (update)

In development [GID-NG10177] Expected publication date: 19 April 2023

Type

NICE guideline

Status

In development
Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: 21 April 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Clostridioides difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 23 July 2021

Type

Antimicrobial prescribing guideline

Status

In development
Cenobamate for focal onset seizures in epilepsy [ID1553]

In development [GID-TA10661] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Liposomal bupivacaine for treating postoperative pain [ID3799]

Proposed [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibalizumabtreating for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Proposed [GID-TA10657] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]

In development [GID-TA10710] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Proposed [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

In development [GID-TA10639] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management

In development [GID-NG10091] Expected publication date: 21 April 2021

Type

NICE guideline

Status

In development
Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488

In development [GID-TA10432] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

In development [GID-TA10470] Expected publication date: 27 January 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]

In development [GID-TA10472] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (Review of TA397) [ID1591]

In development [GID-TA10626] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]

In development [GID-TA10703] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selective internal radiation therapies for treating hepatocellular carcinoma [ID1276]

In development [GID-TA10381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]

In development [GID-TA10406] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]

In development [GID-TA10482] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer (CDF review TA484) [ID1572]

In development [GID-TA10513] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]

In development [GID-TA10650] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]

In development [GID-TA10612] Expected publication date: 21 July 2021

Type

Technology appraisal guidance

Status

In development
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]

In development [GID-TA10619] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]

In development [GID-TA10624] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357

In development [GID-TA10322] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Intrapartum care for healthy women and babies (update)

In development [GID-NG10174] Expected publication date: 22 March 2023

Type

NICE guideline

Status

In development
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

In development [GID-TA10555] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pelvic floor dysfunction: prevention and non-surgical management

In development [GID-NG10123] Expected publication date: 09 December 2021

Type

NICE guideline

Status

In development
Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 10 May 2022

Type

NICE guideline

Status

In development
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Proposed [GID-TA10764] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for managing overweight and obesity [ID3850]

Proposed [GID-TA10765] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Transvenous obliteration of varices

In development [GID-IPG10206] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Image-guided cryoablation of peripheral neuroma for chronic pain

In development [GID-IPG10208] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease

In development [GID-IPG10209] Expected publication date: TBC

Type

Interventional procedures guidance

Status

In development
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Spasticity (after stroke) - botulinum toxin type A [ID768]

In development [GID-TAG499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]

In development [GID-TA10105] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

In development [GID-TA10089] Expected publication date: 15 November 2017

Type

Technology appraisal guidance

Status

In development
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

In development [GID-TA10527] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Secondary infection of common skin conditions including eczema: antimicrobial prescribing

In development [GID-NG10135] Expected publication date: 02 March 2021

Type

Antimicrobial prescribing guideline

Status

In development
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

In development [GID-TA10458] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Eculizumab for treating relapsing neuromyelitis optica [ID1271]

In development [GID-TA10469] Expected publication date: 02 September 2020

Type

Technology appraisal guidance

Status

In development
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

In development [GID-TA10313] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

In development [GID-TA10450] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

In development [GID-TA10524] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]

In development [GID-TA10430] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development